proderm, in cooperation with Bayer Consumer Care AG and Bayer Hispania S.L., has investigated the use of a liquid cleansing product in two clinical studies on adults and children with atopic-prone skin. The results of the studies were recently published in the 'Journal of Cosmetic Dermatology'.
Gentle cleansing of the skin without further compromising its barrier function and moisture content and being simultaneously devoid of adverse effects on the skin microbiome are important features of body cleansers for atopic-prone skin sufferers. For this population, a new dexpanthenol-containing liquid cleanser (DCLC) was developed.
Two prospective 4-week studies have been conducted. Study 1 investigated the effect of once-daily DCLC on stratum corneum (SC) hydration, transepidermal water loss (TEWL), skin pH, and skin microbiome (all on the volar forearm) in adult subjects with dry skin (N = 44). Study 2 explored the cutaneous tolerability of DCLC and its effect on the microbiome biodiversity of the volar forearm skin in infants/children with atopic-prone skin (N = 33, aged 6 months to 6 years). In the latter study, DCLC was applied 2–3 days/week in combination with an emollient applied at least twice daily.
You can request the publication via this link.
